IE65891B1 - Preparation of non-recemic furo[3,4-c]pyridine derivatives - Google Patents
Preparation of non-recemic furo[3,4-c]pyridine derivativesInfo
- Publication number
- IE65891B1 IE65891B1 IE162891A IE162891A IE65891B1 IE 65891 B1 IE65891 B1 IE 65891B1 IE 162891 A IE162891 A IE 162891A IE 162891 A IE162891 A IE 162891A IE 65891 B1 IE65891 B1 IE 65891B1
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- general formula
- enantiomer
- furo
- group
- Prior art date
Links
- QYNDTTJOWNQBII-UHFFFAOYSA-N furo[3,4-c]pyridine Chemical class C1=NC=CC2=COC=C21 QYNDTTJOWNQBII-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 108090000371 Esterases Proteins 0.000 claims abstract description 14
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 27
- BFJMHTOBRRZELQ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-c]pyridine Chemical class N1=CC=C2C(I)=NNC2=C1 BFJMHTOBRRZELQ-UHFFFAOYSA-N 0.000 claims description 8
- 108090001060 Lipase Proteins 0.000 claims description 8
- 239000004367 Lipase Substances 0.000 claims description 8
- 102000004882 Lipase Human genes 0.000 claims description 8
- 235000019421 lipase Nutrition 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960002376 chymotrypsin Drugs 0.000 claims description 3
- -1 «-chymotrypsin Proteins 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 abstract description 4
- 125000002252 acyl group Chemical group 0.000 abstract description 3
- 108010027597 alpha-chymotrypsin Proteins 0.000 abstract description 2
- 125000001424 substituent group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 7
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 150000002440 hydroxy compounds Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CFYIUBWVKZQDOG-UHFFFAOYSA-N 4-[[2-[[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(NC(=O)CNC(=O)CNC(=O)CCC(=O)O)CC1=CC=CC=C1 CFYIUBWVKZQDOG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- CVKNDPRBJVBDSS-UHFFFAOYSA-N Cicletanine Chemical compound O1CC2=C(O)C(C)=NC=C2C1C1=CC=C(Cl)C=C1 CVKNDPRBJVBDSS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/523,238 US5130252A (en) | 1990-05-14 | 1990-05-14 | Resolution of furopyridine enantiomers and synthetic precursors thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
IE911628A1 IE911628A1 (en) | 1991-11-20 |
IE65891B1 true IE65891B1 (en) | 1995-11-29 |
Family
ID=24084213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE162891A IE65891B1 (en) | 1990-05-14 | 1991-05-13 | Preparation of non-recemic furo[3,4-c]pyridine derivatives |
Country Status (32)
Country | Link |
---|---|
US (1) | US5130252A (de) |
JP (1) | JPH05117277A (de) |
KR (1) | KR910020015A (de) |
AR (1) | AR247762A1 (de) |
AT (1) | AT400445B (de) |
AU (1) | AU642368B2 (de) |
BE (1) | BE1007016A3 (de) |
CA (1) | CA2042421C (de) |
CH (1) | CH682488A5 (de) |
DE (1) | DE4115681C2 (de) |
DK (1) | DK88991A (de) |
DZ (1) | DZ1499A1 (de) |
ES (1) | ES2033574B1 (de) |
FI (1) | FI97807C (de) |
FR (1) | FR2661919B1 (de) |
GB (1) | GB2244056B (de) |
GR (1) | GR1001593B (de) |
HK (1) | HK131993A (de) |
IE (1) | IE65891B1 (de) |
IT (1) | IT1248743B (de) |
LU (1) | LU87935A1 (de) |
MA (1) | MA22154A1 (de) |
MY (1) | MY107567A (de) |
NL (1) | NL194615C (de) |
NO (1) | NO180308C (de) |
NZ (1) | NZ238009A (de) |
OA (1) | OA09352A (de) |
PT (1) | PT97657B (de) |
SE (1) | SE510808C2 (de) |
TN (1) | TNSN91035A1 (de) |
TW (1) | TW226998B (de) |
ZA (1) | ZA913461B (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0221494D0 (en) * | 2002-09-16 | 2002-10-23 | Generics Uk Ltd | Novel processes for the preparation of 1.3-dihydro-6-methylfuro (3,4-c) pyndin derivatives |
US20110251396A1 (en) * | 2003-07-17 | 2011-10-13 | Gilead Sciences, Inc. | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
US20060089374A1 (en) * | 2003-07-17 | 2006-04-27 | Glenn Cornett | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
US20050043391A1 (en) * | 2003-07-17 | 2005-02-24 | Fong Benson M. | Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
GB2423927A (en) * | 2003-08-29 | 2006-09-13 | Cotherix Inc | Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome |
US20060154959A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and carvedilol |
CA2593793A1 (en) * | 2005-01-05 | 2006-07-13 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
US20070141174A1 (en) * | 2005-01-13 | 2007-06-21 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
US20080096915A1 (en) * | 2005-01-13 | 2008-04-24 | Greenberg Traurig LLP | Compositions for the treatment of metabolic disorders |
US20070105817A1 (en) * | 2005-11-09 | 2007-05-10 | Jim Page | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
JP2010514841A (ja) * | 2007-01-03 | 2010-05-06 | グレン ブイ. コルネット, | 肺疾患および心疾患の処置におけるシクレタニンおよびpkc阻害剤 |
EP2498605B1 (de) * | 2009-10-29 | 2014-08-27 | Merck Sharp & Dohme Corp. | Diuretika |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN156817B (de) * | 1981-02-10 | 1985-11-09 | Scras | |
US4985365A (en) * | 1981-11-28 | 1991-01-15 | Sumitomo Chemical Company, Ltd. | Process for producing optically active benzyl alcohol compound |
EP0101076B1 (de) * | 1982-08-13 | 1989-01-04 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Verfahren zur Herstellung von optisch aktiven Oxazolidinon-Derivaten |
IN160104B (de) * | 1983-04-05 | 1987-06-27 | Scras | |
JPS59216590A (ja) * | 1983-05-24 | 1984-12-06 | Ube Ind Ltd | 光学活性フエニルプロパルギルアルコ−ル誘導体の製法 |
GB8327817D0 (en) * | 1983-10-18 | 1983-11-16 | Scras | 4-halo-furo-(3 4-c)-pyridine derivatives |
GB8330517D0 (en) * | 1983-11-16 | 1983-12-21 | Scras | 6-vinyl-furo-(3,4-c)pyridine derivatives |
GB8330658D0 (en) * | 1983-11-17 | 1983-12-29 | Scras | 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives |
GB8402740D0 (en) * | 1984-02-02 | 1984-03-07 | Scras | Furo-(3 4-c)-pyridine derivatives |
JPS60224494A (ja) * | 1984-04-24 | 1985-11-08 | Nissan Chem Ind Ltd | α−メチルベンジルアルコ−ル類の光学分割法 |
GB8414559D0 (en) * | 1984-06-07 | 1984-07-11 | Scras | Pyridine derivatives |
GB8427218D0 (en) * | 1984-10-27 | 1984-12-05 | Scras | Pyridine derivatives |
JPS61289899A (ja) * | 1985-06-18 | 1986-12-19 | Kanegafuchi Chem Ind Co Ltd | 光学活性2−ハロ−1−フエニルエタノ−ルおよびそのエステルの製造法 |
US4916074A (en) * | 1986-10-30 | 1990-04-10 | Chisso Corporation | Process for producing optically active compounds |
JP2691986B2 (ja) * | 1987-08-28 | 1997-12-17 | チッソ株式会社 | ピリジン骨格を有する光学活性化合物の製造法 |
DE3737335A1 (de) * | 1987-11-04 | 1989-05-18 | Basf Ag | Verfahren zur herstellung eines biokatalysators und dessen verwendung zur razematspaltung |
GB8808001D0 (en) * | 1988-04-06 | 1988-05-05 | Scras | Stereospecific preparative process for furol(3,4-c)pyridine derivatives |
DE3990349T1 (de) * | 1988-04-06 | 1990-04-26 | Scras | Stereospezifisches verfahren zur herstellung von enantiomeren von furo(3,4-c)pyridin, so erhaltene verbindungen und therapeutische zusammensetzungen auf basis dieser verbindungen |
NL8801311A (nl) * | 1988-05-20 | 1989-12-18 | Stamicarbon | Fenylglycidaatstereoisomeren, omzettingsprodukten daarvan met 2-nitrothiofenol en de bereiding van diltiazem. |
GB8907480D0 (en) * | 1989-04-03 | 1989-05-17 | Scaras Societe De Conseils De | Separation of insomers of furo(3,4-c)pyridine derivatives |
GB8917168D0 (en) * | 1989-07-27 | 1989-09-13 | Scras | Asymmetric synthesis of furo(3,4-c)pyridine derivatives |
-
1990
- 1990-05-14 US US07/523,238 patent/US5130252A/en not_active Expired - Lifetime
-
1991
- 1991-04-24 GR GR910100180A patent/GR1001593B/el not_active IP Right Cessation
- 1991-04-29 AU AU76200/91A patent/AU642368B2/en not_active Ceased
- 1991-05-01 NZ NZ238009A patent/NZ238009A/en unknown
- 1991-05-01 NL NL9100749A patent/NL194615C/nl not_active IP Right Cessation
- 1991-05-02 CH CH1318/91A patent/CH682488A5/fr not_active IP Right Cessation
- 1991-05-07 ZA ZA913461A patent/ZA913461B/xx unknown
- 1991-05-07 GB GB9109810A patent/GB2244056B/en not_active Expired - Fee Related
- 1991-05-08 IT ITMI911255A patent/IT1248743B/it active IP Right Grant
- 1991-05-08 DZ DZ910055A patent/DZ1499A1/fr active
- 1991-05-08 MY MYPI91000775A patent/MY107567A/en unknown
- 1991-05-10 AR AR91319663A patent/AR247762A1/es active
- 1991-05-13 SE SE9101431A patent/SE510808C2/sv not_active IP Right Cessation
- 1991-05-13 AT AT0098291A patent/AT400445B/de not_active IP Right Cessation
- 1991-05-13 DK DK088991A patent/DK88991A/da not_active Application Discontinuation
- 1991-05-13 CA CA002042421A patent/CA2042421C/en not_active Expired - Fee Related
- 1991-05-13 KR KR1019910007684A patent/KR910020015A/ko not_active Application Discontinuation
- 1991-05-13 BE BE9100441A patent/BE1007016A3/fr not_active IP Right Cessation
- 1991-05-13 ES ES9101157A patent/ES2033574B1/es not_active Expired - Fee Related
- 1991-05-13 FI FI912315A patent/FI97807C/fi active
- 1991-05-13 NO NO911852A patent/NO180308C/no not_active IP Right Cessation
- 1991-05-13 MA MA22424A patent/MA22154A1/fr unknown
- 1991-05-13 TN TNTNSN91035A patent/TNSN91035A1/fr unknown
- 1991-05-13 IE IE162891A patent/IE65891B1/en not_active IP Right Cessation
- 1991-05-14 FR FR9105766A patent/FR2661919B1/fr not_active Expired - Lifetime
- 1991-05-14 PT PT97657A patent/PT97657B/pt not_active IP Right Cessation
- 1991-05-14 LU LU87935A patent/LU87935A1/fr unknown
- 1991-05-14 DE DE4115681A patent/DE4115681C2/de not_active Expired - Lifetime
- 1991-05-14 OA OA59998A patent/OA09352A/xx unknown
- 1991-05-14 JP JP3109203A patent/JPH05117277A/ja active Pending
- 1991-07-09 TW TW080105317A patent/TW226998B/zh active
-
1993
- 1993-12-02 HK HK1319/93A patent/HK131993A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI104488B (fi) | Monoklavulanaattisuola polyamiinien kanssa | |
IE65891B1 (en) | Preparation of non-recemic furo[3,4-c]pyridine derivatives | |
EP0175312B1 (de) | Verfahren zur Herstellung von optisch aktiven Hydantoinen | |
EP0853624B1 (de) | Verfahren zur herstellung von galanthamin und deren derivaten | |
CA2161849A1 (en) | Production of optically active compounds | |
CA2230826A1 (en) | Galanthamine derivatives and process for their preparation | |
US4865771A (en) | Process for preparing L(-)-carnitine chloride from 3,4-epoxybutyric esters and novel intermediate compounds | |
US3838008A (en) | Stereoselective preparation of l-dopa and l-m-tyrosine and novel compounds | |
US5883264A (en) | Process for preparing optically active trans-3-phenylglycidamide compounds | |
KR100451413B1 (ko) | 클루이베로마이시스 마르시아누스의 카르보닐 환원효소를이용한 카르보닐 화합물의 환원반응 | |
US6780635B2 (en) | Process for the preparation of optically active azabicyclo heptanone derivatives | |
NO328110B1 (no) | Fremgangsmate for fremstilling av bisykliske forbindelser og anvendelse av fremgangsmaten til fremstilling av en ICE-inhibitorforbindelse | |
HU213569B (en) | Enzymatic process for the stereoselective preparation of a heterobicyclic alcohol enantiomer | |
EP1348765A1 (de) | Verfahren zur Herstellung von optisch aktiven Azabicycloheptanone-Derivaten | |
HUT45262A (en) | New process for producing penicillin derivatives | |
ES2228274A1 (es) | Sintesis quimioenzimatica de (+)-citalopram y (-)-citalopram. | |
ITMI950234A1 (it) | Procedimento per la preparazione di penem | |
JPH01156993A (ja) | マクロライド化合物の製法 | |
MXPA97001992A (en) | Procedure for preparing compounds of trans-3-phenylglicidamide optically acti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |